Abstract
Objective
The study objective was to evaluate the therapeutic effect of cannabidiol (CBD) on a combination of caecal slurry, lipopolysaccharide (LPS), and Escherichia coli (E. coli)-induced systemic inflammatory response syndrome (SIRS) in male Sprague Dawley rats.
Methods
The therapeutic activity was monitored in behavioral tests and inflammatory biomarkers by the enzyme-linked immune sorbent assay (ELISA) method.
Results
Behavioral tasks were significantly increased like a tail flick response by 73.84% (p ≤ 0.001), grip strength by 33.56% (p ≤ 0.028), locomotor activity by 20.71% (p = 0.034) in the CBD (60 mg/kg) group compared to disease control (DC) group. Levels of inflammatory serum biomarkers like interleukin-1β (IL-1β), matrix metallopeptidase-9 (MMP-9), IL-6, and tumor necrosis factor-alpha (TNF-α) were significantly decreased by 29.56 (p = 0.041), 71.20 (p ≤ 0.001), 35.05 (p ≤ 0.001), and 75.56% (p = 0.002), respectively, in the CBD-60 compared with DC. Inflammatory cytokines levels, viz. IL-1β, MMP-9, IL-6, and TNF-α, in the liver were significantly (p ≤ 0.001) decreased by 81.01, 40.41, 22.84, and 69.46%, respectively, in CBD-60 to DC. Similarly, levels of inflammatory cytokines such as IL-1β and MMP-9 in the kidney were significantly (p ≤ 0.001) decreased by 80.90 and 43.93%, respectively, in CBD-60 compared to DC.
Conclusion
Taken together, results suggest that CBD treatment significantly improved behavioral tasks and decreased the level of inflammatory cytokines under SIRS conditions that might provide an opportunity to manage acute and chronic inflammatory disorders.
Graphical abstract
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The datasets generated during and/or analyzed during the current study will be available from the corresponding author on reasonable request.
Abbreviations
- CBD:
-
Cannabidiol
- E. coli :
-
Escherichia coli
- SIRS:
-
Systemic inflammatory response syndrome
- ELISA:
-
Enzyme-linked immune sorbent assay
- DC:
-
Disease control
- IL-1β:
-
Interleukin-1β
- MMP-9:
-
Matrix metallopeptidase-9
- TNF-α:
-
Tumor necrosis factor-alpha
- CPCSEA:
-
Committee for the Purpose of Control and Supervision of Experiment on Animals
- IAEC:
-
Institutional Animal Ethical Committee
- CMC:
-
Carboxymethylcellulose
- ANOVA:
-
One-way analysis of variance
- NC:
-
Normal control
- DEX:
-
Dexamethasone
- CI:
-
Confidence interval
- GPR55:
-
G protein-coupled receptor 55
- CB1 :
-
Cannabinoid 1
- α3 GlyRs:
-
Alpha 3 glycine receptors
- TRPV1:
-
Transient receptor potential cation channel subfamily V member 1
- 5-HT1A :
-
5-Hydroxy tryptamine 1A
References
Angus DC, van der Poll T (2013) Severe sepsis and septic shock. N Engl J Med 369:840–851
Atalay S, Jarocka-Karpowicz I, Skrzydlewska E (2019) Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (basel). https://doi.org/10.3390/antiox9010021
Avraham Y, Grigoriadis N, Poutahidis T, Vorobiev L, Magen I, Ilan Y, Mechoulam R, Berry E (2011) Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. Br J Pharmacol 162(7):1650–1658. https://doi.org/10.1111/j.1476-5381.2010.01179.x
Buras JA, Holzmann B, Sitkovsky M (2005) Animal models of sepsis: setting the stage. Nat Rev Drug Discov 4:854–865
Chakraborty RK, Burns B (2021) Systemic inflammatory response syndrome. [Updated 2020 Nov 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547669/. Accessed 8 Nov 2021
De Gregorio D, McLaughlin RJ, Posa L, Ochoa-Sanchez R, Enns J, Lopez-Canul M, Aboud M, Maione S, Comai S, Gobbi G (2019) Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain 160(1):136–150. https://doi.org/10.1097/j.pain.0000000000001386
Genaro K, Fabris D, Arantes ALF, Zuardi AW, Crippa JAS, Prado WA (2017) Cannabidiol is a potential therapeutic for the affective-motivational dimension of incision pain in rats. Front Pharmacol 8:391. https://doi.org/10.3389/fphar.2017.00391
Hammell DC, Zhang LP, Ma F, Abshire SM, McIlwrath SL, Stinchcomb AL, Westlund KN (2016) Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain 20(6):936–948. https://doi.org/10.1002/ejp.818
Jones NA, Glyn SE, Akiyama S, Hill TD, Hill AJ, Weston SE, Burnett MD, Yamasaki Y, Stephens GJ, Whalley BJ, Williams CM (2012) Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 21(5):344–352. https://doi.org/10.1016/j.seizure.2012.03.001
Kaukonen KM, Bailey M, Pilcher D, Cooper DJ, Bellomo R (2015) Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med 372(17):1629–1638
Lewis AJ, Seymour CW, Rosengart MR (2016) Current murine models of sepsis. Surg Infect (larchmt) 17(4):385–393
Maggio M, Guralnik JM, Longo DL, Ferrucci L (2006) Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci 61(6):575–584
McPartland JM, Duncan M, Di Marzo V, Pertwee RG (2015) Are cannabidiol and Delta(9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 172(3):737–753. https://doi.org/10.1111/bph.12944
Mlost J, Bryk M, Starowicz K (2020) Cannabidiol for pain treatment: focus on pharmacology and mechanism of action. Int J Mol Sci 21(22):8870. https://doi.org/10.3390/ijms21228870/
Opal SM (2010) Endotoxins and other sepsis triggers. Contrib Nephrol 167:14–24
Park KS, Choi KH, Kim YS, Hong BS, Kim OY, Kim JH, Yoon CM, Koh GY, Kim YK, Gho YS (2010) Outer membrane vesicles derived from Escherichia coli induce systemic inflammatory response syndrome. PLoS ONE 5(6):e11334. https://doi.org/10.1371/journal.pone.0011334
Ramabadran K, Bansinath M, Turndorf H, Puig MM (1989) Tail immersion test for the evaluation of a nociceptive reaction in mice. Methodological considerations. J Pharmacol Methods 21(1):21–31
Ramnath RD, Weing S, He M, Sun J, Zhang H, Singh Bawa M, Bhatia M (2006) Inflammatory mediators in sepsis: cytokines, chemokines, adhesion molecules and gases. J Organ Dysfunct 2(2):80–92
Schleicher EM, Ott FW, Müller M, Silcher B, Sichler ME, Löw MJ, Wagner JM, Bouter Y (2019) Prolonged cannabidiol treatment lacks on detrimental effects on memory, motor performance and anxiety in C57BL/6J mice. Front Behav Neurosci 7(13):94. https://doi.org/10.3389/fnbeh.2019.00094
Shiotsuki H, Yoshimi K, Shimo Y, Funayama M, Takamatsu Y, Ikeda K, Takahashi R, Kitazawa S, Hattori N (2010) A rotarod test for evaluation of motor skill learning. J Neurosci Methods 189(2):180–185
Starr ME, Steele AM, Saito M, Hacker BJ, Evers BM, Saito H (2014) A new cecal slurry preparation protocol with improved long-term reproducibility for animal models of sepsis. PLoS ONE. https://doi.org/10.1371/journal.pone.0115705
Sun A, Chia JS, Chang YF, Chiang CP (2002) Serum interleukin-6 level is a useful marker in evaluating therapeutic effects of levamisole and Chinese medicinal herbs on patients with oral lichen planus. J Oral Pathol Med 31(4):196–203
Suryavanshi SV, Kovalchuk I, Kovalchuk O (2021) Cannabinoids as key regulators of inflammasome signaling: a current perspective. Front Immunol 11:613613. https://doi.org/10.3389/fimmu.2020.613613
Takac B, Mihaljević S, Stefanić M, Glavas-Obrovac L, Kibel A, Samardzija M (2014) Importance of interleukin 6 in pathogenesis of inflammatory bowel disease. Coll Antropol 38(2):659–664
Tatem KS, Quinn JL, Phadke A, Yu Q, Gordish-Dressman H, Nagaraju K (2014) Behavioral and locomotor measurements using an open field activity monitoring system for skeletal muscle diseases. J vis Exp 91:51785
Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150(5):613–623. https://doi.org/10.1038/sj.bjp.0707133
Vincent JL, Opal SM, Marshall JC, Tracey KJ (2013) Sepsis definitions: time for change. Lancet 381(9868):774–775
Xiong W, Cui T, Cheng K, Yang F, Chen SR, Willenbring D, Guan Y, Pan HL, Ren K, Xu Y, Zhang LJ (2012) Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. Exp Med 209(6):1121–1134
Ye Q, Wang B, Mao J (2020) The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect 80(6):607–613. https://doi.org/10.1016/j.jinf.2020.03.037
Young WA, Fallon EA, Heffernan DS, Efron PA, Cioffi WG, Ayala A (2017) Improved survival after induction of sepsis by cecal slurry in PD-1 knockout murine neonates. Surgery 161(5):1387–1393
Acknowledgements
The authors extend their sincere thanks and gratitude to Dabur Research Foundation, India, for providing the facilities and support that enabled the successful completion of the work.
Author information
Authors and Affiliations
Contributions
MKT: contributes to the concept and design of the work. SCM: analysis and interpretation of data with manuscript preparation. MG: analysis and interpretation of data with drafting the work. SJ: revised manuscript critically for important intellectual content; and final approval of the version to be published.
Corresponding author
Ethics declarations
Conflict of interest
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors declare that they have no competing interests related to this work.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Trivedi, M.K., Mondal, S., Gangwar, M. et al. Anti-inflammatory potential of cannabidiol (CBD) on combination of caecal slurry, LPS, and E. coli-induced systemic inflammatory response syndrome (SIRS) in Sprague Dawley Rats. Inflammopharmacol 30, 225–232 (2022). https://doi.org/10.1007/s10787-021-00901-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-021-00901-z